A PHASE 1A/1B, FIRST-IN-HUMAN, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RGT-61159 FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY ADENOID CYSTIC CARCINOMA (ACC) OR COLORECTAL CARCINOMA (CRC)

Registry ID

RGT61159-01

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

RGENTA THERAPEUTICS INC.

Start date

2026-07-10

Last update

2024-06-05

Conditions

• COLORECTAL CARCINOMA
• ADENOID CYSTIC CARCINOMA (ACC)

Related clinical trials

• IN VIVO LUNG PERFUSION (IVLP) AS AN ADJUVANT TREATMENT FOR PATIENTS WITH RESECTABLE OR UNRESECTABLE PULMONARY METASTASES OF COLORECTAL CARCINOMAS
• A PHASE III STUDY OF PEMBROLIZUMAB (MK-3475) VS CHEMOTHERAPY IN MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) STAGE IV COLORECTAL CARCINOMA (KEYNOTE-177)
• A PHASE II STUDY OF PEMBROLIZUMAB (MK-3475) AS MONOTHERAPY IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC (STAGE IV) MISMATCHED REPAIR DEFICIENT OR MICROSATELLITE INSTABILITY-HIGH COLORECTAL CARCINOMA (KEYNOTE-164)

View on source registry